Immix Biopharma raises $9.1M in PIPE; Nancy Chang appointed to board

Immix Biopharma, Inc.

Sold 3,831,216 shares at $2.37/share and warrants for 2,873,417 shares at $2.00/share.
Gross proceeds ~$9.1M for working capital and general corporate purposes; closed on Sept 5, 2025.
Warrants are non-transferable, exercisable for 10 years, and only for cash.
Nancy Chang, Ph.D. appointed to board effective Sept 8, 2025; co-founded Tanox (XOLAIR developer).
Resale registration statement to be filed with SEC within 30 days of closing.

item 1.01item 3.02item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.